<DOC>
	<DOCNO>NCT00004110</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody locate tumor cell either kill deliver tumor kill substance without harm normal cell . Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining monoclonal antibody therapy chemotherapy may kill tumor cell . PURPOSE : Phase II trial study effectiveness monoclonal antibody therapy plus etoposide treating patient neuroblastoma .</brief_summary>
	<brief_title>Monoclonal Antibody Therapy Plus Etoposide Treating Patients With Neuroblastoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine antitumor effect monoclonal antibody 3F8 , etoposide , isotretinoin use standard image method tumor marker study patient high-risk neuroblastoma . - Assess progression-free survival patient treatment . - Assess effect oral etoposide human anti-mouse antibody anti-idiotype response patient . OUTLINE : Patients stratify accord disease status ( evaluable measurable vs second subsequent remission measurable evaluable disease ) . Patients receive monoclonal antibody 3F8 ( MOAB 3F8 ) IV 1.5 hour daily day 1-10 oral etoposide daily day 29-49 . Treatment repeat every 8 week 4 course absence disease progression , human anti-mouse antibody ( HAMA ) response , unacceptable toxicity . If HAMA fail develop completion 4 course MOAB 3F8 , patient continue treatment MOAB 3F8 day 1-5 every 8 week HAMA reach great 1,000 U/mL month 24 , whichever occur first . Beginning completion 4 course etoposide MOAB 3F8 HAMA develops , patient receive oral isotretinoin twice daily 14 day follow least 14-day rest . Treatment repeat total 6 course . PROJECTED ACCRUAL : A total 50 patient ( 25 per stratum ) accrue study within 5 year .</detailed_description>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Isotretinoin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Highrisk neuroblastoma : Histopathology OR Bone marrow involvement plus elevated urinary catecholamine Prior tumor progression standard chemotherapy poor longterm prognosis indicate 1 following : Nmyc amplification tumor cell Diploid chromosomal content plus lp loss heterozygosity tumor cell Distant skeletal metastasis Unresectable primary tumor infiltrate across midline More 10 % tumor cell bone marrow Less 30 % chance longterm progressionfree survival Evaluable ( microscopic marrow metastasis , elevate tumor marker , abnormal bone scan MIBG PET scan ) measurable ( CT scan , MRI ) disease document least 4 week completion prior systemic therapy No rapidly progressive disease define 1 following : Serum lactic dehydrogenase great 1.5 time upper limit normal due tumor An opiate requirement pain tumor Greater 25 % increase tumor successive imaging study Life expectancy le 8 week Second subsequent remission chemotherapy and/or radiotherapy allow provide less 30 % chance survival No prior myelodysplastic syndrome leukemia PATIENT CHARACTERISTICS : Age : Not specify Performance status : Not specify Life expectancy : See Disease Characteristics At least 8 week Hematopoietic : Not specify Hepatic : No grade 3 bad liver toxicity Renal : No grade 3 bad renal toxicity Creatinine clearance least 60 mL/min Cardiovascular : No grade 3 bad cardiac toxicity Pulmonary : No grade 3 bad pulmonary toxicity Other : Not pregnant No grade 3 bad gastrointestinal toxicity No grade 3 bad neurologic system toxicity No grade 4 hearing deficit No active lifethreatening infection No prior exposure mouse antibody human antimouse antibody great 1,000 ELISA units/mL No allergy mouse proteins PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics Endocrine therapy : Not specify Radiotherapy : See Disease Characteristics Surgery : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>regional neuroblastoma</keyword>
	<keyword>disseminate neuroblastoma</keyword>
	<keyword>recurrent neuroblastoma</keyword>
	<keyword>localize unresectable neuroblastoma</keyword>
</DOC>